Germany Ophthalmic Drugs Market Size & Outlook, 2025-2030
Related Markets
Germany ophthalmic drugs market highlights
- The Germany ophthalmic drugs market generated a revenue of USD 2,114.3 million in 2024 and is expected to reach USD 3,343.0 million by 2030.
- The Germany market is expected to grow at a CAGR of 7.9% from 2025 to 2030.
- In terms of segment, anti-vegf agents was the largest revenue generating drug class in 2024.
- Gene & Cell Therapy is the most lucrative drug class segment registering the fastest growth during the forecast period.
Ophthalmic drugs market data book summary
| Market revenue in 2024 | USD 2,114.3 million |
| Market revenue in 2030 | USD 3,343.0 million |
| Growth rate | 7.9% (CAGR from 2025 to 2030) |
| Largest segment | Anti-vegf agents |
| Fastest growing segment | Gene & Cell Therapy |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Anti-Allergy, Anti-VEGF agents, Anti-glaucoma, Gene & Cell Therapy, Anti-inflammatory |
| Key market players worldwide | Pfizer Inc, Alcon Inc, Novartis AG ADR, Bausch Health Companies Inc, Merck & Co Inc, Regeneron Pharmaceuticals Inc, AbbVie Inc, Bayer AG, Genentech, Nicox SA Share from reverse split, Coherus BioSciences Inc |
Other key industry trends
- In terms of revenue, Germany accounted for 5.5% of the global ophthalmic drugs market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany ophthalmic drugs market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 2,755.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Ophthalmic Drugs Market Scope
Ophthalmic Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Nicox SA Share from reverse split | View profile | 29 | Rue Evariste Galois, Emerald Square, Batiment C, Sundesk Sophia Antipolis, Biot, France, 06410 | https://www.nicox.com |
| Coherus BioSciences Inc | View profile | 306 | 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, United States, 94065 | https://www.coherus.com |
| Genentech | View profile | 10001+ | South San Francisco, California, United States, North America | http://gene.com |
| Bausch Health Companies Inc | View profile | 20270 | 2150 Saint Elzear Boulvard West, Laval, QC, Canada, H7L 4A8 | https://www.bauschhealth.com |
| Regeneron Pharmaceuticals Inc | View profile | 13450 | 777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707 | https://www.regeneron.com |
| Bayer AG | View profile | 99723 | Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 | https://www.bayer.com |
| Merck & Co Inc | View profile | 72000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | https://www.merck.com |
| Alcon Inc | View profile | 25315 | Chemin de Blandonnet 8, Royce Bedward, Vernier, Geneva, Switzerland, 1214 | https://www.alcon.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| AbbVie Inc | View profile | 50000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | http://www.abbvieinvestor.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
Germany ophthalmic drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to ophthalmic drugs market will help companies and investors design strategic landscapes.
Anti-vegf agents was the largest segment with a revenue share of 33.35% in 2024. Horizon Databook has segmented the Germany ophthalmic drugs market based on anti-allergy, anti-vegf agents, anti-glaucoma, gene & cell therapy, anti-inflammatory covering the revenue growth of each sub-segment from 2018 to 2030.
Germany has a strong healthcare system, which covers 90% of the population under mandatory health insurance coverage. This allows easy access of the population to treatments, facilitating the adoption of ophthalmic drugs.
Technological advancements and the increasing prevalence of ophthalmic diseases are driving the demand for ophthalmic drugs in Germany. Furthermore, factors such as increasing demand for personalized medicines and a number of healthcare establishments catering to the geriatric population, along with favorable government initiatives, are anticipated to drive market growth during the forecast period.
An increase in the number of partnerships between educational institutions and hospitals to gain insights into R&D is expected to propel the demand for ophthalmic drugs in the country.
Reasons to subscribe to Germany ophthalmic drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Germany ophthalmic drugs market databook
-
Our clientele includes a mix of ophthalmic drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany ophthalmic drugs market , including forecasts for subscribers. This country databook contains high-level insights into Germany ophthalmic drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Germany ophthalmic drugs market size, by drug class, 2018-2030 (US$M)
Germany Ophthalmic Drugs Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
